Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246662 · ClinicalTrials.gov registry record · Phase 1
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
A Phase 1 study of Myelodysplastic Syndromes and Leukemia, Myeloid, Chronic, sponsored by Sunesis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 5
- Study locations
NCT00246662: Completed Phase 1 study of Myelodysplastic Syndromes and Leukemia, Myeloid, Chronic, sponsored by Sunesis Pharmaceuticals.
NCT00246662 is a Phase 1 study of Myelodysplastic Syndromes and Leukemia, Myeloid, Chronic that has completed, run by Sunesis Pharmaceuticals. The registered enrollment target is 75 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (74% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00246662, a Phase 1 study of Myelodysplastic Syndromes and Leukemia, Myeloid, Chronic, has completed, sponsored by Sunesis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study primarily determined the safety and tolerability of escalating doses of vosaroxin (SNS-595) in 2 dose schedules, and assessed the PK profile of vosaroxin and defined a recommended dose regimen for Phase 2 studies. Secondarily the study assessed potential biomarkers and antileukemic activity.
Conditions Studied
Interventions
- DRUG Vosaroxin
Study Locations (5)
Florida
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Indiana
- Indiana University Cancer Center - Indianapolis
Maryland
- Johns Hopkins Hospital - Baltimore
New Mexico
- New Mexico Cancer Care Alliance - Albuquerque
Texas
- University of Texas, MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-11-14 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
What the finished NCT00246662 record still lists
NCT00246662 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (74% lower).
The record links to 4 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Vosaroxin is the first listed.
NCT00246662 lists 5 locations in 5 states (Florida, Indiana, Maryland).
Frequently Asked Questions
What is clinical trial NCT00246662 about?
NCT00246662 is a clinical study titled "Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies". This study primarily determined the safety and tolerability of escalating doses of vosaroxin (SNS-595) in 2 dose schedules, and assessed the PK profile of vosaroxin and defined a recommended dose regimen for Phase 2 studies. Secondarily the study assessed potential biomarkers and antileukemic activi...
What is the current status of trial NCT00246662?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2005-11-14. Estimated completion is 2009-04.
What conditions does trial NCT00246662 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic, Leukemia, Lymphocytic, Acute, Leukemia, Nonlymphocytic, Acute.
What interventions are being tested in trial NCT00246662?
The interventions under investigation include: Vosaroxin (DRUG).
Who is sponsoring clinical trial NCT00246662?
This trial is sponsored by Sunesis Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00246662 being conducted?
This trial has 5 study locations across Florida, Indiana, Maryland, New Mexico, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00246662's enrollment target sits among peer trials
75 70th of 173 higher than 102 of 173 other Myelodysplastic Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
RECRUITING · Phase 1
-
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI